Some of India’s bigger pharmaceutical companies are ramping up investment to grow their biotechnology business. Biocon has invested $200 million in an insulin manufacturing unit in Malaysia. Lupin and Wockhardt are increasing their investments to produce new insulins and biosimilars (officially approved versions of original ‘innovator’ products, which can be manufactured when the original product’s patent expires.
“Our plant in Malaysia is undergoing validation; we are yet to start commercial production. Each year, we are investing Rs 100-150 crore in India and our focus now is to file four biosimilar products for diabetes and oncology globally,” said Chief Executive Officer Arun Chandavarkar.